Home / Europe / France / Life Sciences & Healthcare

Life Sciences & Healthcare

Our law firm – by your side to meet the challenges of today and tomorrow

Health sector companies are now facing unprecedented challenges, from pricing pressure to the growing threat from IP-infringement, digitalisation, tighter regulatory requirements imposed by the French, European and international authorities.

Against a backdrop of increased competition, you need to remain innovative and efficient. You therefore need to adapt to, and even anticipate, changes to the regulatory and operational framework. This means responding to increasingly complex questions and having access to specialist advice.

Our lawyers have particular expertise in the following areas:

  • regulatory advice and assistance (drugs, medical devices and cosmetics): legal environment surrounding clinical trials, questions relating to personal health data, advertising and promotional campaigns for healthcare products, appeals against decisions relating to marketing authorisations and reimbursements;
  • mergers & acquisitions involving health sector companies: structuring of acquisitions, divestitures and partnerships both in France and internationally, advice and support throughout all phases of the transaction (due diligence, drafting of the legal documentation, transaction implementation, etc.);
  • protection of industrial property (patents, trademarks, etc.) and confidential information: filing, monitoring, contract negotiation (R&D, licences, etc.) and related disputes (infringement actions, IP revocation actions and disputes with employee-inventors);
  • compliance: anti-corruption/FCPA, promotion best practice, declaration of interests and anti-gift regulation;
  • product liability: assistance and representation before the courts;
  • antitrust/competition: assistance with the management and definition of commercial policy, parallel imports, quotas, merger control notifications of M&A transaction in the healthcare sector, training and review of internal procedures in the event of competition investigations; compliance with rules on restrictive competition practices (invoicing, payment deadlines, etc.) and assistance in case of an inspection
  • advice and assistance in relation to sector-specific taxes and customs issues (tariff classification, customs value...).

A highly specialised team, able to adapt to all situations

In addition to the specific expertise required in relation to health, our overall understanding of the scientific, business and ethical elements that underpin your activities allows us to provide the most strategic response to each of your issues.

Our team of lawyers covers a large range of different specialisms, is widely recognised for its expertise and has a very high level of credibility both with public authorities and all sector stakeholders. We have also an extensive track record on M&A transactions in the healthcare sector (including in particular M&A in the sectors of private hospitals and healthcare facilities as well as medical biology) and we have the experience and knowledge to manage complex, international transactions as efficiently as possible. Whether you are a major international group marketing blockbusters, a small company with a very specific business activity or a biotech, we can provide you with long-term assistance with advisory and litigation services, both in France and internationally.

Choose area

Cosmétiques
Secteur fortement compétitif, les produits cosmétiques sont soumis à une réglementation de plus en plus dense ; l’intervention d’avocats spécialistes
Our Tax Team
Our Em­ploy­ment & Pen­sions Team
Our Cor­por­ate/M&A Team

Feed

18/01/2023
What is the sig­ni­fic­ance of a clin­ic­al tri­al pro­tocol as pri­or art at the...
The EPO Ap­peal Board has fur­ther re­fined their view on when pri­or art dis­clos­ures of clin­ic­al tri­al pro­to­cols are an is­sue for pat­entab­il­ity of med­ic­al use claims. De­cision T1806/18 In de­cision T1806/18...
23/12/2022
2023 Sea­son's Greet­ings from CMS Fran­cis Le­fe­b­vre
Watch our wishes for a happy and pros­per­ous New Year 2023 in video be­low.me­di­um­Click here to dis­cov­er our Sea­son’s Greet­ings card
12/12/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Fa­cing the op­por­tun­it­ies...
Di­git­al ad­vances and in­nov­at­ive ther­apies are push­ing the bound­ar­ies of health and the leg­al world has to keep pace Life sci­ences are fizz­ing with in­genu­ity and in­nov­a­tion with re­volu­tion­ary gene and...
05/12/2022
EU Com­mis­sion pro­poses to mod­ern­ise product li­ab­il­ity rules for green and...
Cur­rent product li­ab­il­ity rules, based on the 85/374/EGK Product Li­ab­il­ity Dir­ect­ive (PLD), are nearly 40 years old and no longer suit­able for the mod­ern di­git­al age. Among oth­er things, the PLD is un­cer­tain...
22/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Life Sci­ences are reap­ing...
Di­git­al trans­form­a­tion in life sci­ences is cre­at­ing op­por­tun­it­ies to counter health­care’s most in­tract­able prob­lems from treat­ing rare dis­eases to ac­cel­er­at­ing dia­gnostics and re­du­cing treat­ment back­logs...
09/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: The Life Sci­ences sec­tor...
The open­ing of COP27 has brought an in­tense glob­al fo­cus on cli­mate change and the tower­ing de­mands needed to reach car­bon net zero and to pro­tect the en­vir­on­ment. United Na­tions Gen­er­al Sec­ret­ary Ant­o­nio...
02/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: The leg­al sec­tor has a key...
The United Na­tions has pledged to use its pur­chas­ing fire­power to ac­cel­er­ate sus­tain­ab­il­ity along the health­care sup­ply chan­nel and called on the leg­al sec­tor to sup­port its ef­forts. Law­yers are crit­ic­al...
20/09/2022
Skin­teg­rated Cos­me­ceut­ic­als - is Pharma be­com­ing sexy (again?)
Case Study: Skin­tegra, Skin­teg­rity Cos­me­ceut­ic­als are sexy right now.  They’re less reg­u­lated than the phar­ma­ceut­ic­al in­dustry (al­though don’t let that fool you in­to be­liev­ing you can say whatever...
15/09/2022
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
Rules ap­plic­able to the ad­vert­ising of veter­in­ary medi­cines are not ad­dressed in this ques­tion­naire. 1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? 1.1 Medi­cines...
13/09/2022
UPC Rules of Pro­ced­ure go in­to force with judg­ments to be made pub­lic
The entry in­to force of the Rules of Pro­ced­ure is part of the fi­nal pre­par­a­tions for the United Pat­ent Court (UPC), which is cur­rently ex­pec­ted to start work in early 2023. After the bod­ies of the UPC...
08/09/2022
Can­nabis law and le­gis­la­tion in France
Med­ic­al use In prin­ciple, pur­su­ant to Art­icle R. 5132-86-1 of the French Pub­lic Health Code (PHC), the cul­ture, man­u­fac­ture, trans­port, im­port, ex­port, hold­ing, of­fer, trans­fer, ac­quis­i­tion and use of...
30/08/2022
Phar­ma­ceut­ic­al trade marks - a real pain in the bum?
An EU IPO Case Study: Proc­to­LYSY­AL v PRO­COTOL­IZ­IN Sum­mary I al­ways like to start at the end.  No nasty sur­prises and you know what to ex­pect.  In this case study, the trade marks ‘proc­to­LYSY­AL’...